Relaxin 2/RXFP1 signaling induces cell invasion via the β-catenin pathway in endometrial cancer

Misaki Fue, Yasuhiro Miki, Kiyoshi Takagi, Chiaki Hashimoto, Nobuo Yaegashi, Takashi Suzuki, Kiyoshi Ito

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Relaxin is known to play an important role in animal pregnancies, including those of humans. It is suggested that relaxin induces aggressive cell growth and invasiveness in several types of cancer, including endometrial cancer. However, the mechanisms of relaxin remain largely unclear. In this study, we examined the effects of relaxin 2 (RLN2), the major circulating relaxin in humans, on human endometrial carcinoma cell lines. RLN2 treatment induced invasion in HEC-1B and Ishikawa cells. RLN2-induced cell invasion was significantly decreased by transfection of relaxin receptor 1 (RXFP1) siRNAs. The β-catenin inhibitor, XAV939, also significantly inhibited the RLN2-induced cell invasions. Both a decrease of cadherin expression and an increase of β-catenin phosphorylation were observed in response to the RLN2 treatment in HEC-1B and Ishikawa cells. We then examined RLN2 and RXFP1 expression in 80 human endometrioid endometrial carcinoma tissues. RLN2 immunoreactivity was detected in the human endometrial carcinoma cells and had a correlative tendency with histological grade and RXFP1. These results suggest that adherens junctions in cancer cells are weakened by the breakdown of the cadherin/catenin complex, which is induced by β-catenin phosphorylation via RLN2/RXFP1 signaling.

Original languageEnglish
Article number2438
JournalInternational Journal of Molecular Sciences
Issue number8
Publication statusPublished - 2018 Aug 18


  • Endometrial cancer
  • Phospho-β-catenin
  • Relaxin 2
  • RXFP1


Dive into the research topics of 'Relaxin 2/RXFP1 signaling induces cell invasion via the β-catenin pathway in endometrial cancer'. Together they form a unique fingerprint.

Cite this